Cargando…

Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data

BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in var...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouwels, Koen B., Bozdemir, Sefika E., Yegenoglu, Selen, Celebi, Solmaz, McIntosh, E. David, Unal, Serhat, Postma, Maarten J., Hacimustafaoglu, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045176/
https://www.ncbi.nlm.nih.gov/pubmed/27689356
http://dx.doi.org/10.1371/journal.pone.0163567
_version_ 1782457071061434368
author Pouwels, Koen B.
Bozdemir, Sefika E.
Yegenoglu, Selen
Celebi, Solmaz
McIntosh, E. David
Unal, Serhat
Postma, Maarten J.
Hacimustafaoglu, Mustafa
author_facet Pouwels, Koen B.
Bozdemir, Sefika E.
Yegenoglu, Selen
Celebi, Solmaz
McIntosh, E. David
Unal, Serhat
Postma, Maarten J.
Hacimustafaoglu, Mustafa
author_sort Pouwels, Koen B.
collection PubMed
description BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. OBJECTIVES: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. METHODS: A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. RESULTS: Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. CONCLUSION: RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.
format Online
Article
Text
id pubmed-5045176
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50451762016-10-27 Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data Pouwels, Koen B. Bozdemir, Sefika E. Yegenoglu, Selen Celebi, Solmaz McIntosh, E. David Unal, Serhat Postma, Maarten J. Hacimustafaoglu, Mustafa PLoS One Research Article BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. OBJECTIVES: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. METHODS: A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. RESULTS: Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. CONCLUSION: RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita. Public Library of Science 2016-09-30 /pmc/articles/PMC5045176/ /pubmed/27689356 http://dx.doi.org/10.1371/journal.pone.0163567 Text en © 2016 Pouwels et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pouwels, Koen B.
Bozdemir, Sefika E.
Yegenoglu, Selen
Celebi, Solmaz
McIntosh, E. David
Unal, Serhat
Postma, Maarten J.
Hacimustafaoglu, Mustafa
Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title_full Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title_fullStr Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title_full_unstemmed Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title_short Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
title_sort potential cost-effectiveness of rsv vaccination of infants and pregnant women in turkey: an illustration based on bursa data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045176/
https://www.ncbi.nlm.nih.gov/pubmed/27689356
http://dx.doi.org/10.1371/journal.pone.0163567
work_keys_str_mv AT pouwelskoenb potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT bozdemirsefikae potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT yegenogluselen potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT celebisolmaz potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT mcintoshedavid potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT unalserhat potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT postmamaartenj potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata
AT hacimustafaoglumustafa potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata